Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)

Konference: 2014 56th ASH Annual Meeting - účast ČR

Kategorie: Myelodysplastický syndrom

Téma: 637. Myelodysplastic Syndromes – Clinical Studies: Molecular Characterization and Lower Risk MDS

Číslo abstraktu: 409

Autoři: MD Valeria Santini; MD Antonio Medina Almeida, PhD; MD Aristoteles Giagounidis, PhD; MD Stephanie Gröpper; doc. MUDr. Anna Jonášová, Ph.D.; MD Norbert Vey, PhD; Ghulam J. Mufti, DM, FRCP, FRCPath; MD Rena Buckstein; M.D. Moshe Mittelman; MD Uwe Platzbecker; MD Ofer Shpilberg, MPH; MD Ron Ram; MD Consuelo del Canizo, PhD; MD Norbert Gattermann; MD Keiya Ozawa, PhD; Jim Zhong, PhD; Francis Séguy; MD Albert Hoenekopp; MD C.L. Beach; MD Pierre Fenaux, PhD

Datum přednesení příspěvku: 8. 12. 2014